HebeBio Makes Significant Progress in GLP-1 Obesity Treatment Development

Singapore – November 15, 2024 – HebeBio announces significant advancements in its GLP-1 research program, demonstrating promising results in pre-clinical studies. The company's innovative approach to obesity treatment continues to show potential for improved patient outcomes. 

The research team has successfully completed initial optimization of the Bispecific GLP-1 RA candidate, showing enhanced efficacy in reducing muscle mass loss while maintaining weight reduction benefits. These findings represent a crucial step forward in addressing one of the key challenges in current obesity treatments. The company's proprietary technology platform has enabled the development of a more targeted therapeutic approach. 

For more information about our research and development programs, visit our Solutions page.